Why Is SYNDAX PHARMACEUTICA (SNDX) Stock Down Today?

By the Top Tier Newswire AI Desk · October 13, 2026 at 10:16 AM ET · reviewed against 14 wire stories

SYNDAX PHARMACEUTICA (SNDX) is down -16.71% in the latest session. Our newswire has captured 14 stories on SNDX across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 34/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Syndax Pharmaceuticals (SNDX) shares fell 16.71% to $13.79 on Tuesday. The sharp decline followed the announcement that the company’s Phase 2 trial of axatilimab for idiopathic pulmonary fibrosis failed to meet its primary endpoint. Syndax stated it does not plan further development of the drug for this indication.

What Happened

Syndax disclosed that the MAXPIRe Phase 2 study of axatilimab in idiopathic pulmonary fibrosis did not achieve the primary endpoint measuring annualized forced vital capacity decline. The company confirmed it will halt plans for further IPF development of the asset. Following the news, BofA lowered its price target on the stock to $23 from $26. Citi noted that the selloff creates an attractive entry point, while H.C. Wainwright stated that the company’s valuation remains unchanged after the trial miss.

What The Data Shows

The stock opened at $13.74, representing a 17.0% gap down from the prior close of $16.55. Trading volume reached 2.2 million shares, which is 1.2 times the three-month daily average. The session high was $15.49 at 7:35 AM ET, while the low hit $13.49 at 9:55 AM ET. Syndax has a market capitalization of $1.5 billion and is currently unprofitable with a trailing twelve-month EPS of -$2.51. Revenue increased 223.7% over the same period, though the net margin stands at -87.5%. The stock has a beta of 0.42 and a 52-week range of $12.99 to $25.59. Over the last eight sessions, the stock declined 10.9% from $18.58 to $16.55. On October 13, 2026, the stock printed one fresh 52-week high and 14 fresh 52-week lows.

What To Watch

Investors will monitor the broader coverage of the trial results and subsequent analyst reactions. The company’s next scheduled earnings date is not provided in the current data set.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

SNDX by the numbers

Last: $13.79Session: -16.71%7 sessions: -10.93%Coverage: 14 stories / 7 sourcesAI sentiment: 34/100 (bearish)Mkt cap: $1.5B52w: $12.99 to $25.59

SNDX · today's session (5-min) · -16.80% vs prior close · updated 10:15 AM ET

AI sentiment, last 36h · averaged over 14 stories · 34/100 bearish

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline

6h agoThe FlyBEARISH 42Analyst

Syndax valuation unchanged after trial miss, says H.C. Wainwright

6h agoThe FlyBULLISH 64Analyst

Syndax selloff brings attractive entry point, says Citi

6h agoInvesting.com MarketsBEARISH 38General

Why is Syndax Pharmaceuticals stock sliding today?

7h agoMarketChameleonBEARISH 34Earnings

Syndax halts axatilimab IPF plans after MAXPIRe misses FVC decline endpoint October 13, 2026

Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint measuring annualized FVC decline, and the company does not plan further IPF development. The company emphasized axatilimab was well tolerated with no new safety signals and said the results do not affect ongoing cGVHD trials, with additional readouts expected later this year and in early 2028.

9h agoThe FlyBEARISH 34Analyst

Syndax price target lowered to $23 from $26 at BofA

21h agoStocktwits NewsBEARISH 22Earnings

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis.

22h agoSeeking AlphaBEARISH 14Earnings

Syndax plummets as IPF asset axatilimab fails in phase 2 trial

Syndax (SNDX) plunges after hours as axatilimab fails Phase 2 idiopathic pulmonary fibrosis endpoint.

23h agoThe FlyBEARISH 22Earnings

Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on SNDX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier SNDX move explainers: 2026-10-13